Waypoint Capital, a private investment firm focused on sophisticated capital, through an affiliate has acquired a 70 percent stake in Allergy Partners, a single-specialty allergy and asthma practice group.
AP has grown into a large allergy and asthma services platform. The firm operates 62 practice hubs with 135 physicians in 20 states to facilitate over 300,000 annual patient encounters. The firm will be led by current CEO, David Brown.
“Allergy Partners is a clear industry leader with a strong culture of growth and innovation, which makes this an exciting opportunity for both Waypoint and Allergy Partners to maximize the existing footprint and evolve through organic and transformative initiatives,” commented Waypoint Capital.
“Our mission is to be leaders in the development and delivery of high-quality health care for patients with asthma and allergic disease,” added David Brown, AP CEO. “Our partnership with Waypoint will further that mission as we continue to execute on our strategic initiatives, further build our vast care network, and promote continued research and innovation in the field of allergy and asthma care.”
McDermott Will & Emery acted as legal counsel and SVB Leerink acted as exclusive financial advisor to Waypoint.